Circulating microRNA Biomarkers of Thiazide Response in Hypertension
Open Access
- 20 February 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (4) , e032433
Abstract
Background: Thiazide diuretics are the second most frequently prescribed class of antihypertensives, but up to 50% of patients with hypertension have minimal antihypertensive response to thiazides. We explored circulating microRNAs (miRNAs) in search of predictive biomarkers of thiazide response. Methods and Results: We profiled 754 miRNAs in baseline plasma samples of 36 hypertensive European American adults treated with hydrochlorothiazide, categorized into responders (n=18) and nonresponders (n=18) on the basis of diastolic blood pressure response to hydrochlorothiazide. miRNAs with ≥2.5‐fold differential expression between responders and nonresponders were considered for validation in 3 cohorts (n=50 each): hydrochlorothiazide‐treated European Americans, chlorthalidone‐treated European Americans, and hydrochlorothiazide‐treated Black individuals. Different blood pressure phenotypes including categorical (responder versus nonresponder) and continuous diastolic blood pressure and systolic blood pressure were tested for association with the candidate miRNA expression using multivariate regression analyses adjusting for age, sex, and baseline blood pressure. After quality control, 74 miRNAs were available for screening, 19 of which were considered for validation. In the validation cohort, miR‐193b‐3p and 30d‐5p showed significant associations with continuous SBP or diastolic blood pressure response or both, to hydrochlorothiazide in European Americans at Benjamini‐Hochberg adjusted P P <0.05. Predicted target genes of the 5 miRNAs were mapped to key hypertension pathways: lysine degradation, fatty acid biosynthesis, and metabolism. Conclusions: The above identified circulating miRNAs may have a potential for clinical use as biomarkers for thiazide diuretic selection in hypertension. Registration: URL: ClinicalTrials.gov . Unique identifiers: NCT00246519 , NCT01203852 , NCT00005520 .Keywords
This publication has 34 references indexed in Scilit:
- DIANA-miRPath v3.0: deciphering microRNA function with experimental supportNucleic Acids Research, 2015
- On non-detects in qPCR dataBioinformatics, 2014
- Impact of CYP2D6 Polymorphisms on Clinical Efficacy and Tolerability of Metoprolol TartrateClinical Pharmacology & Therapeutics, 2014
- Genomic Association Analysis of Common Variants Influencing Antihypertensive Response to HydrochlorothiazideHypertension, 2013
- Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure responseJournal of Translational Medicine, 2012
- MicroRNAs in Hypertension: Mechanisms and Therapeutic TargetsCurrent Hypertension Reports, 2011
- Pharmacogenomics of antihypertensive drugs: Rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studyAmerican Heart Journal, 2009
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008
- PGC-1α Gly482Ser Polymorphism Associates With Hypertension Among Danish WhitesHypertension, 2005
- Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertensionKidney International, 2002